MS-STAT2 Phase 3 Clinical Drug Trial.

MS-Stat2 logo

MS-STAT2 is a UK-wide phase 3 clinical drug trial which will test simvastatin, a drug used to lower cholesterol, in people with the secondary progressive form of MS (SPMS).

The research will be led by Dr Jeremy Chataway, UCL Institute of Neurology, who led the phase 2 trial into simvastatin that was published in The Lancet in 2014. It involved 140 people with secondary progressive MS and found that those taking high doses of the drug (simvastatin) had a significant reduction in the rate of brain atrophy (brain shrinkage) over two years and also had better disability scores at the end of the study. The authors concluded that high doses of simvastatin might be a treatment option for SPMS in the future.

It is hoped that the phase 3 of the MS-STAT trial will establish definitively whether simvastatin is able to slow the rate of disability progression over a three year period in people with SPMS. 

We hope to recruit 90 people from the Lothian area into the MS-STAT2 trial. The trial involves regular visits to the Anne Rowling Clinic to have neurological examinations, blood tests, walking distance tests and cognitive testing.

Am I eligible?

People diagnosed with secondary progressive MS may be eligible if they:

  • are aged between 25-65
  • have an EDSS (Expanded Disability Status Scale) of between 4.0 & 6.5 aided/unaided
  • and are not currently taking a statin

There are other eligibility criteria so the best way to find out if you are eligible is to speak with the trial research nurse Dawn Lyle on 0131 465 9512.

Study documentation:  patient information leaflet

Funding Acknowledgements

This study is supported by the Anne Rowling Regenerative Neurology Clinic, and funded by MS Society, UCL and the National Institute for Health Research.